Last10K.com

Nrx Pharmaceuticals, Inc. (NRXP) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

Nrx Pharmaceuticals, Inc.

CIK: 1719406 Ticker: NRXP
Cover - shares
3 Months Ended
Mar. 31, 2022
May 11, 2022
Document Type10-Q 
Entity Registrant NameNRX Pharmaceuticals, Inc. 
Entity Central Index Key0001719406 
Entity Filer CategoryNon-accelerated Filer 
Amendment Flagfalse 
Document Period End DateMar. 31, 2022 
Document Fiscal Year Focus2022 
Document Fiscal Period FocusQ1 
Current Fiscal Year End Date--12-31 
Entity File Number001-38302 
Entity Tax Identification Number82-2844431 
Entity Small Businesstrue 
Entity Emerging Growth Companytrue 
Entity Ex Transition Periodtrue 
Entity Shell Companyfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity Interactive Data CurrentYes 
Entity Current Reporting StatusYes 
Entity Incorporation, State or Country CodeDE 
Entity Address, State or ProvinceDE 
Entity Address, Address Line One1201 Orange Street 
Entity Address, Address Line TwoSuite 600 
Entity Address, City or TownWilmington 
Entity Address, Postal Zip Code19801 
City Area Code484 
Local Phone Number254-6134 
Entity Common Stock, Shares Outstanding 66,641,314
Common Stock  
Title of 12(b) SecurityCommon Stock, par value $0.001 per share 
Trading SymbolNRXP 
Security Exchange NameNASDAQ 
Common stock warrant [Member]  
Title of 12(b) SecurityWarrants to purchase one share of Common Stock 
Trading SymbolNRXPW 
Security Exchange NameNASDAQ 

View differences made from one quarter to another to evaluate Nrx Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nrx Pharmaceuticals, Inc..

Continue

Assess how Nrx Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nrx Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
M & A
Revenue
Other
Filter Subcategory:
All
Shares
Expense
Cash Flow
Income
Product
Other
Inside Nrx Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Stockholders Equity (Parenthetical)
Condensed Consolidated Statements Of Stockholders' Equity
Accrued And Other Current Liabilities
Accrued And Other Current Liabilities (Details)
Accrued And Other Current Liabilities (Tables)
Commitments And Contingencies
Commitments And Contingencies - Gem Share Subscription Facility Agreement (Details)
Commitments And Contingencies - Operating Lease (Details)
Commitments And Contingencies - Relief Therapeutics Collaboration Agreement (Details)
Commitments And Contingencies - Sponsored Research Agreement With National Jewish Health (Details)
Commitments And Contingencies - Zyesami Agreements (Details)
Equity
Equity (Tables)
Equity - Assumed Placement Warrants (Details)
Equity - Assumed Public Warrants (Details)
Equity - Common And Preferred Stock (Details)
Equity - Preferred Investment Options (Details)
Equity - Schedule Of Warrant Activity (Details)
Equity - Stock Options (Details)
Equity - Substitute Warrants (Details)
Fair Value Measurements
Fair Value Measurements (Details)
Fair Value Measurements (Tables)
Fair Value Measurements - Reconciliation Of Earnout Cash Liability (Details)
Fair Value Measurements - Reconciliation Of Warrant Liabilities (Details)
Fair Value Measurements - Warrant Liability (Details)
Income Taxes
Income Taxes (Details)
Liquidity
Liquidity (Details)
Notes Payable
Notes Payable (Tables)
Notes Payable - Additional Information (Details)
Notes Payable - Summary Of Outstanding Notes Payable (Details)
Organization
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Details)
Prepaid Expenses And Other Current Assets (Tables)
Related Party Transactions
Related Party Transactions (Details)
Reverse Recapitalization
Reverse Recapitalization (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 2016 Omnibus Incentive Plan (Details)
Stock-Based Compensation - 2016 Omnibus Incentive Plan, Fair Value Assumptions (Details)
Stock-Based Compensation - 2021 Omnibus Incentive Plan (Details)
Stock-Based Compensation - Option Awards, Assumptions (Details)
Stock-Based Compensation - Recognition Of Stock-Based Compensation (Details)
Stock-Based Compensation - Summary Of Stock Option Activity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Ticker: NRXP
CIK: 1719406
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-22-008948
Submitted to the SEC: Mon May 16 2022 4:08:29 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/nrxp/0001558370-22-008948.htm